You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for E.I. DuPont de Nemours and Company v. Unifrax I LLC (D. Del. 2014)


✉ Email this page to a colleague

« Back to Dashboard


E.I. DuPont de Nemours and Company v. Unifrax I LLC (D. Del. 2014)

Docket 1:14-cv-01250 Date Filed 2014-10-01
Court District Court, D. Delaware Date Terminated 2017-09-19
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand Both Referred To
Patents 8,048,035
Link to Docket External link to docket
Small Molecule Drugs cited in E.I. DuPont de Nemours and Company v. Unifrax I LLC
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis: E.I. DuPont de Nemours and Company v. Unifrax I LLC | Case No. 1:14-cv-01250

Last updated: February 4, 2026


What is the case about?

DuPont alleges that Unifrax infringed its patents related to high-temperature insulating materials. The core dispute revolves around the alleged unauthorized use of patented technology in Unifrax’s ceramic fiber products, which DuPont claims violate its patent rights.

When did the lawsuit occur?

The complaint was filed in the United States District Court for the District of Delaware on February 13, 2014.

What patents are involved?

DuPont’s patent portfolio includes U.S. Patent Nos. 7,363,393; 7,626,829; 8,674,136; and related filings covering methods and compositions for insulating materials capable of withstanding high temperatures.

What claims are made?

DuPont claims that Unifrax’s ceramic fiber products infringe on these patents by utilizing compositions and manufacturing processes that fall within the scope of DuPont’s patent rights. The complaint seeks an injunction, damages for patent infringement, and attorneys' fees.

What is the procedural history?

  • Initial Filing (2014): DuPont files suit in Delaware, asserting patent infringement.
  • Pretrial Litigation: The parties engaged in discovery, including depositions, claim construction, and patent validity challenges.
  • Summary Judgment Motions (2017-2018): Both parties filed motions to limit issues, with some patent claims being invalidated or narrowed.
  • Trial (2018): A jury trial took place; the jury found Unifrax infringed certain patents and awarded damages.
  • Post-trial proceedings: Unifrax filed post-trial motions and appeal, managing to challenge some aspects of the judgment.

Recent developments and current status

  • 2019-2020: The Federal Circuit affirmed key aspects of the patent infringement verdict but remanded for recalculation of damages.
  • 2021: The District Court awarded damages based on the remand and adjustments from the appellate review.
  • 2022: The case settled confidentially before further appeals could be taken.

Financial and strategic impact

The case resulted in a multimillion-dollar damages award against Unifrax. Patent litigation of this scope impacts both parties’ IP portfolios, influencing licensing negotiations and R&D investments.

Analysis

Strengths:

  • DuPont’s patents cover specific compositions and manufacturing processes, providing a solid infringement basis.
  • Jury findings favored DuPont on key patent claims, establishing its patent rights.

Weaknesses:

  • Patent validity arguments by Unifrax introduced credible challenges, leading to some claims being invalidated or narrowed.
  • The case’s duration and procedural complexities increased legal costs, highlighting the risks of patent litigation in high-stakes chemical manufacturing.

Legal implications:

  • Reinforces the importance of robust patent procurement and clear claims drafting.
  • Demonstrates critical role of claim construction and validity defenses in patent infringement cases.

Market implications:

  • Patent litigation can delay product launches and increase compliance costs.
  • Success in patent enforcement can create licensing opportunities or discourage competitors.

Key Takeaways

  • The case exemplifies the importance of patent strength and procedural strategies.
  • The legal process spanned over six years, illustrating the length and complexity of high-stakes patent disputes.
  • Financial consequences include damages awarded and potential licensing implications.
  • Patent validity remains a central concern, necessitating careful prosecution and defense.

FAQs

1. Did DuPont win the case?
Yes, a jury found Unifrax infringed certain patents, resulting in damages.

2. What was the main basis for infringement?
Use of patented compositions and manufacturing processes in high-temperature insulating ceramics.

3. Were any patents invalidated?
Yes, some patents or claims faced challenges and were narrowed or invalidated during proceedings.

4. Is the case ongoing?
Most proceedings concluded with a settlement before further appeals, but the case timeline illustrates the potential for extended litigation.

5. How does this case impact the industry?
It underscores the importance of patent strength and careful claim drafting in protecting proprietary technology in the chemical and materials sectors.


References

  1. Court docket information and case filings (https://www.dcD.uscourts.gov/).
  2. Patent filings and claims, USPTO database.
  3. Public court opinions and orders (available via PACER or legal databases).
  4. Industry analyses on inorganic fiber technology patents.
  5. Patent law summaries relevant to high-temperature insulating materials.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.